Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine.
Prior studies suggest that supplemental treatment with thyroid hormone may enhance the patient's response in depression resistant to tricyclic antidepressants. The authors report on the lack of efficacy of adjunctive L-triiodothyronine (T3; 25 micrograms/day) in a sample of 20 outpatient unipolar depressives who had not responded to greater than or equal to 12 weeks of treatment with imipramine (mean dosage = 240 mg/day) and interpersonal psychotherapy. The overall response rate after 4 weeks of T3 was low (25%); the outcome did not differ significantly from a matched historical comparison group who received continued tricyclic treatment but not T3.
Thase
M E
ME
Department of Psychiatry, University of Pittsburgh School of Medicine.
Kupfer
D J
DJ
Jarrett
D B
DB
D000328:Adult; D000553:Ambulatory Care; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004334:Drug Administration Schedule; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D010043:Outcome and Process Assessment, Health Care; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D014284:Triiodothyronine / Q000627:therapeutic use*
D014284:Triiodothyronine; D007099:Imipramine